Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO GU 2024

25 - 27 Jan 2024

Moscone Center, San Francisco, United States of America

Pembrolizumab a promising option for MIUC patients after radical surgery

Dr Andrea Apolo - National Cancer Institute, Bethesda, USA

Pembrolizumab a promising option for MIUC patients after radical surgery ( Dr Andrea Apolo - National Cancer Institute, Bethesda, USA )

ASCO GU 2024: Current best practice for mRCC

Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu

ASCO GU 2024: Current best practice for mRCC ( Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu )

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer

Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi...

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer ( Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi Kitamura )

Remote genetic testing has the potential to increase the uptake of testing in...

Dr Bruce Montgomery - University of Washington, Seattle, USA

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems ( Dr Bruce Montgomery - University of Washington, Seattle, USA )

Stockholm3 offers a promising avenue for personalised risk-based prostate...

Dr Scott Eggener - The University of Chicago, Chicago, USA

Stockholm3 offers a promising avenue for personalised risk-based prostate cancer diagnosis ( Dr Scott Eggener - The University of Chicago, Chicago, USA )

Subcutaneous delivery of nivolumab is effective in treating metastatic ccRCC

Dr Saby George - Roswell Park Comprehensive Cancer Center, New York, USA

Subcutaneous delivery of nivolumab is effective in treating metastatic ccRCC ( Dr Saby George - Roswell Park Comprehensive Cancer Center, New York, USA )

Cabozantinib and atezolizumab show more efficacy compared to second NHT in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Baseline characteristics of patients with PSMA-PET–positive and –negative...

Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )

Enfortumab vedotin in combination with pembrolizumab is a potential new...

Dr Michiel Simon Van Der Heijden - Netherlands Cancer Institute, Amsterdam...

Enfortumab vedotin in combination with pembrolizumab is a potential new standard of care for 1L la/mUC ( Dr Michiel Simon Van Der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

Lenvatinib and pembrolizumab show promising efficacy in first-line treatment of...

Prof Viktor Grünwald - University Hospital Essen, Essen, Germany

Lenvatinib and pembrolizumab show promising efficacy in first-line treatment of aRCC ( Prof Viktor Grünwald - University Hospital Essen, Essen, Germany )

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with...

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )

Combination of cabozantinib and atezolizumab shows moderate activity in...

Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain

Combination of cabozantinib and atezolizumab shows moderate activity in treating metastatic adrenocortical carcinoma ( Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain )

More from ecancer